Stockscreener 앱 받기
1.75
19.35%
-0.42
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
OKYO Pharma prices public offering at $1.85/share to raise up to $20M - MSN
Published on: 2026-02-14 12:01:38 - baoquankhu1.vn
Small cap wrap: OKYO Pharma, HIVE Digital Technologies, Synchronoss Technologies... - Proactive financial news
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Sees Significant Increase in Short Interest - MarketBeat
What risks investors should watch in OKYO Pharma Limited stockJuly 2025 PreEarnings & Weekly Chart Analysis and Trade Guides - mfd.ru
OKYO Pharma announces $20 million public offering of ordinary shares By Investing.com - Investing.com Canada
OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development - TipRanks
OKYO Pharma stock tumbles on $20 million public offering announcement - Investing.com
OKYO Pharma prices $20M offering to fund late-stage eye drug trial - Proactive financial news
OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline - TipRanks
OKYO Pharma announces $20 million public offering of ordinary shares - Investing.com
What’s the analyst consensus on OKYO Pharma LimitedOptions Play & Technical Entry and Exit Tips - mfd.ru
OKYO Pharma Limited Prices Public Offering of Ordinary Shares to Raise Approximately $20 Million - Quiver Quantitative
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares - The Manila Times
Okyo Pharma Ltd Announces Pricing Of $20 Million Public Offering Of Ordinary Shares - TradingView
OKYO Pharma Prices Public Offering at $1.85 per Share - Intellectia AI
Okyo Pharma announces ordinary shares offering, no amount given - TipRanks
OKYO Pharma launches underwritten public offering of ordinary shares - MSN
OKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development - TipRanks
OKYO Pharma Announces Public Offering of Ordinary Shares - Bitget
OKYO Pharma Announces Public Offering of Ordinary Shares - Benzinga
OKYO Pharma Appoints Flavio Mantelli, MD, as Chief Medical Officer - VisionMonday.com
Is OKYO Pharma Limited a potential multi bagger2025 Valuation Update & Weekly Sector Rotation Insights - mfd.ru
Volatility Watch: Will JBG SMITH Properties outperform tech stocksJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Small cap wrap: OKYO Pharma, Arizona Gold & Silver, Standard Uranium, C3 Metals… - Proactive financial news
OKYO Pharma transitions ATM equity offering to Leerink Partners as sales agent - Investing.com Nigeria
OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering - Proactive financial news
OKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push - TipRanks
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners - The Manila Times
OKYO Pharma Limited Transitions ATM Equity Offering to Leerink Partners LLC for Enhanced Capital Access - Quiver Quantitative
OKYO Pharma taps Leerink to raise cash for eye pain treatments - Stock Titan
Is OKYO Pharma Limited a turnaround storyJuly 2025 Snapshot & Low Drawdown Trading Techniques - mfd.ru
How interest rate cuts could boost OKYO Pharma Limited stockCEO Change & Safe Investment Capital Preservation Plans - mfd.ru
OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners - TipRanks
OKYO Pharma appoints former Dompé CMO Flavio Mantelli to lead NCP program - Investing.com Australia
OKYO Pharma appoints former Dompé CMO Flavio Mantelli to lead NCP program By Investing.com - Investing.com South Africa
OKYO Pharma appoints Flavio Mantelli as chief medical officer - Proactive financial news
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer - BioSpace
OKYO Pharma Hires Oxervate Veteran Flavio Mantelli as Chief Medical Officer to Drive Urcosimod Program - TipRanks
Doctor behind $1B rare-disease eye drug joins OKYO Pharma - Stock Titan
What are OKYO Pharma Limited’s growth leversJuly 2025 Analyst Calls & Consistent Profit Trade Alerts - mfd.ru
Published on: 2026-02-04 02:26:16 - baoquankhu1.vn
OKYO Pharma’s neuropathic corneal pain study greenlit by FDAICYMI - Proactive financial news
OKYO Pharma to present urcosimod Phase 2 results at ASCRS 2026 annual meeting - Proactive financial news
OKYO Pharma to present urcosimod NCP study results at ASCRS meeting - Investing.com Nigeria
OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial - TipRanks
Small cap wrap: OKYO Pharma, NEXE Innovations, Delivra Health Brands… - Proactive Investors
OKYO Pharma to present urcosimod NCP study results at ASCRS meeting By Investing.com - Investing.com South Africa
OKYO Pharma’s Urcosimod Phase 2 Data Accepted for Presentation at 2026 ASCRS Meeting - TipRanks
1.12%
0.87%
자본화:
|
볼륨(24시간):